Driving innovation in addiction medicine

Indivior is investing in research and development to pioneer life-transforming treatments in addiction medicine, and in partnerships worldwide to realize its vision that all patients will have access to quality treatment for the chronic relapsing conditions and co-occurring disorders of addiction.

Like Comment
Page of
Go to the profile of Indivior


Indivior is a global specialty pharmaceutical company, focused exclusively on addiction medicine. Indivior has a 20-year legacy of health policy and patient advocacy and partnered with the National Institute on Drug Abuse to develop the first buprenorphine-based treatment for opioid use disorder (OUD) in the United States. For more than a decade, Indivior has worked together with stakeholders to support patients. Today, Indivior has a global portfolio of OUD treatments and a pipeline of investigational medicines to address unmet patient needs in OUD and other chronic conditions and co-occurring disorders of addiction, including alcohol use disorder (AUD) and schizophrenia. Putting patients first defines Indivior’s R&D mission: optimizing drug delivery, decreasing dosing frequency, increasing treatment adherence and retention, decreasing diversion and misuse, improving management of overdose, and treating the comorbidities of addiction. At Indivior, our ultimate goal is to transform addiction from a human crisis to a recognized and treated disease. Addiction can be treated. Innovating together, we can take on the opioid crisis and drug addiction and reclaim lives.

No comments yet.